Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotherapy: first do no harm.

Mark H Moss1

  • 1Department of Medicine, Section of Allergy, Pulmonary, and Critical Care Medicine, University of Wisconsin Medical School, K4/934 CSC #9988, University of Wisconsin Hospital and Clinics, 600 Highland Avenue, Madison, WI 53792, USA. mhm@medicine.wisc.edu

Immunology and Allergy Clinics of North America
|May 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined Posterior Tibial Tendon Transfer and Forefoot Reconstruction for Foot Drop and Forefoot Pain Secondary to Charcot-Marie-Tooth Disease: A Case Report and Literature Review.

Cureus·2026
Same author

Effects of combination treatment with tezepelumab and allergen immunotherapy on nasal responses to allergen: A randomized controlled trial.

The Journal of allergy and clinical immunology·2022
Same author

A 2-week medical student curriculum in an outpatient allergy clinic.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2022
Same author

Results of a Phase 2b Trial With GB001, a Prostaglandin D<sub>2</sub> Receptor 2 Antagonist, in Moderate to Severe Eosinophilic Asthma.

Chest·2022
Same author

Short-Term Subcutaneous Allergy Immunotherapy and Dupilumab are Well Tolerated in Allergic Rhinitis: A Randomized Trial.

Journal of asthma and allergy·2021
Same author

Real-world dosing of omalizumab for chronic spontaneous urticaria.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2019
Same journal

Anaphylaxis: State-of-the-Art.

Immunology and allergy clinics of North America·2026
Same journal

Upending Impending Doom.

Immunology and allergy clinics of North America·2026
Same journal

Mast Cell Activation Syndrome and Mimickers.

Immunology and allergy clinics of North America·2026
Same journal

Hereditary Alpha-Tryptasemia (HαT) as a Risk Modifier for Severe Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Emerging Therapies for Anaphylaxis.

Immunology and allergy clinics of North America·2026
Same journal

Novel Epinephrine Delivery Devices.

Immunology and allergy clinics of North America·2026
See all related articles

Allergen immunotherapy effectively treats allergic rhinitis and asthma in children, with potential for preventing future allergies. More pediatric trials are needed to support its widespread use.

Area of Science:

  • Pediatric Allergy and Immunology
  • Clinical Immunology
  • Otolaryngology

Background:

  • Immunotherapy is primarily used by allergists.
  • Pediatric immunotherapy use is limited by a lack of robust clinical trials.
  • Venom immunotherapy has stronger supporting data in children.

Purpose of the Study:

  • To review the current evidence for allergen immunotherapy in children.
  • To highlight the potential of immunotherapy in preventing future allergic diseases.
  • To address the limitations in pediatric clinical trial data.

Main Methods:

  • Review of existing pediatric double-blind, placebo-controlled trials.
  • Analysis of data supporting specific allergen immunotherapy.
  • Evaluation of immunotherapy's role in disease prevention.

Related Experiment Videos

Main Results:

  • Limited pediatric trials exist for specific allergen immunotherapy.
  • Venom immunotherapy data is more conclusive.
  • Immunotherapy can reduce current allergic disease symptoms and complications.

Conclusions:

  • Immunotherapy offers treatment benefits for pediatric allergic rhinitis and asthma.
  • Children may benefit from immunotherapy for preventing future allergic conditions.
  • Further high-quality pediatric trials are essential for broader immunotherapy acceptance.